What question did this study set out to answer?

To evaluate whether an anti-CD11b monoclonal antibody reduces ischemic brain damage and improves functional recovery following transient focal cerebral ischemia.

April 1, 1994Annals of Neurology

Anti‐CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat

View Full Paper

Ask AI

Bookmark

Authors

HCH. ChenHenry Ford Hospital MCMichael ChoppHuman Genome Sciences (United States)RZR. L. ZhangHenry Ford Hospital

Discussion

Member takes

Implication

Animal experiment demonstrates reduced brain lesion volume and improved neurological function in ischemic rats, suggesting targeting CD11b limits reperfusion injury.

Key Points

To evaluate whether an anti-CD11b monoclonal antibody reduces ischemic brain damage and improves functional recovery following transient focal cerebral ischemia.
Rats underwent 2 hours of transient middle cerebral artery occlusion followed by reperfusion.
Animals were assigned to three groups (n=5 per group): MAb 1 (1 mg/kg 1B6c at 0 and 22 hours reperfusion), MAb 2 (initial dose of 2 mg/kg 1B6c), or an isotype-matched control antibody.
Outcomes included body weight, neurological function, histological lesion volume via hematoxylin and eosin at 46 hours post-reperfusion, and polymorphonuclear cell infiltration.
Brain lesion volume was significantly smaller in the MAb 2 group (19.5 ± 1.9%) compared to the MAb 1 (29.9 ± 2.6%) and control (34.2 ± 5.4%) groups (p < 0.01).
MAb 2-treated rats exhibited significantly reduced weight loss and greater improvement in neurological function compared to MAb 1 and vehicle-treated animals (p < 0.05).
Tissue polymorphonuclear cell counts were reduced in both anti-CD11b antibody treatment groups relative to controls.

Cite This Study

Chen et al. (1994) studied this question.

synapsesocial.com/papers/6a72ff4c91c366bb2031e348 https://doi.org/10.1002/ana.410350414

View Full Paper

Ask AI

Bookmark

Implication

Animal experiment demonstrates reduced brain lesion volume and improved neurological function in ischemic rats, suggesting targeting CD11b limits reperfusion injury.

Anti‐CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat

Discussion

Member takes

Implication

Key Points

Cite This Study

Anti‐CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider